Antihypertensive Response to Losartan and Genetic Polymorphisms
Primary Purpose
Hypertension
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
losartan potassium
Comparator: Hydrochlorothiazide
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
- Both gender less than 60 years old, with mild-moderate hypertension (SBP greater than and DBP equal or greater than 90 mmhg, BP < 180/110)
- Never treated for hypertension or who have taken antihypertensive agents sporadically (not more than 15 days total therapy) but not in the 30 days prior to the first visit
- Patient in therapeutic wash out for 6 months
- Patient is asymptomatic, absence of significant concomitant diseases, except for non-familial hypercholesterolemia, absence of systemic diseases
- Women with menopause not treated with hormone replacement therapy or women of reproductive age who do not make use of estro-progestagen agents but who use another safe contraceptive method
- BMI < 30 for men and < 28 for women
Exclusion Criteria:
- Secondary or malignant hypertension, Na <130 mmol/l, K >5,5 mmol/l, or < 3,0 mmol/l
- Cardiac disease such as ischemic, HF, arrhythmia, cardiac surgery
- Pregnant, breast feeding
- History of nephropathy, metabolic disease, liver disease
- Alcohol or drug abuse
- History of angioedema
- Has a known hypersensibility to study drug(s)
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
1
Arm Description
Losartan 50 mg/day for 4 weeks, then doubled to losartan 100 mg/day in case of BP more than 140/90 mm Hg. HCTZ 25 mg will be added at week 8 if BP is more than 140/90 mm Hg. This last regimen will be continued until the end of the study (visit 9-week 48).
Outcomes
Primary Outcome Measures
Blood pressure reduction with reference to genetic polymorphisms.
Secondary Outcome Measures
Full Information
NCT ID
NCT00617877
First Posted
February 5, 2008
Last Updated
July 21, 2009
Sponsor
Merck Sharp & Dohme LLC
1. Study Identification
Unique Protocol Identification Number
NCT00617877
Brief Title
Antihypertensive Response to Losartan and Genetic Polymorphisms
Official Title
Pharmacogenetic of the Antihypertensive Response to the Angiotensin II Blockers in Monotherapy or Associated to Hydrochlorothiazide
Study Type
Interventional
2. Study Status
Record Verification Date
July 2009
Overall Recruitment Status
Completed
Study Start Date
March 2005 (undefined)
Primary Completion Date
June 2009 (Actual)
Study Completion Date
June 2009 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Merck Sharp & Dohme LLC
4. Oversight
5. Study Description
Brief Summary
The purpose of this study is to evaluate the antihypertensive response of treatment with losartan with reference to genetic polymorphisms.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
800 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Description
Losartan 50 mg/day for 4 weeks, then doubled to losartan 100 mg/day in case of BP more than 140/90 mm Hg. HCTZ 25 mg will be added at week 8 if BP is more than 140/90 mm Hg. This last regimen will be continued until the end of the study (visit 9-week 48).
Intervention Type
Drug
Intervention Name(s)
losartan potassium
Intervention Description
Losartan 50 mg/day for 4 weeks, then doubled to losartan 100 mg/day (in case of BP more than 140/90 mm Hg.) Continued until the end of the study (visit 9-week 48).
Intervention Type
Drug
Intervention Name(s)
Comparator: Hydrochlorothiazide
Intervention Description
Hydrochlorothiazide 25 mg will be added at week 8 if BP is more than 140/90 mm Hg. This last regimen will be continued until the end of the study (visit 9-week 48).
Primary Outcome Measure Information:
Title
Blood pressure reduction with reference to genetic polymorphisms.
Time Frame
Over 1 Year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Both gender less than 60 years old, with mild-moderate hypertension (SBP greater than and DBP equal or greater than 90 mmhg, BP < 180/110)
Never treated for hypertension or who have taken antihypertensive agents sporadically (not more than 15 days total therapy) but not in the 30 days prior to the first visit
Patient in therapeutic wash out for 6 months
Patient is asymptomatic, absence of significant concomitant diseases, except for non-familial hypercholesterolemia, absence of systemic diseases
Women with menopause not treated with hormone replacement therapy or women of reproductive age who do not make use of estro-progestagen agents but who use another safe contraceptive method
BMI < 30 for men and < 28 for women
Exclusion Criteria:
Secondary or malignant hypertension, Na <130 mmol/l, K >5,5 mmol/l, or < 3,0 mmol/l
Cardiac disease such as ischemic, HF, arrhythmia, cardiac surgery
Pregnant, breast feeding
History of nephropathy, metabolic disease, liver disease
Alcohol or drug abuse
History of angioedema
Has a known hypersensibility to study drug(s)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Monitor
Organizational Affiliation
Merck Sharp & Dohme LLC
Official's Role
Study Director
12. IPD Sharing Statement
Learn more about this trial
Antihypertensive Response to Losartan and Genetic Polymorphisms
We'll reach out to this number within 24 hrs